Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Demand & Sales by Product Type, Application & Components The global recombinant DNA technology market will witness a robust CAGR of 7.7%, valued at $707.20 billion in 2021, expected to appreciate and reach $1378.76 billion by 2030, confirms Strategic Market Research. Recombinant DNA Technology (rDNA technology) uses enzymes and technology to split or combine a single or multiple genes as required and introduce them into a new organism to achieve a new, desired characteristic. The application of the technology finds itself in fields of agriculture, human therapeutics, vaccine manufacture, poultry industry, high-yield farm animals, and forensics, few among others. The technology uses various types of cells, strata, and media for its application. Two of the most common types of cells used in recombinant DNA technology are yeast cells and bacterial cells. The bacterial cells are used because they contain DNA material outside the chromosomes called a plasmid. This makes the genetic material easier to access for users in rDNA technology. Similarly, yeast cells are also used in the technology as they have active proteins, which are easier to integrate into newer cells. When the genetic material is transferred to a new cell, it is done by using restriction enzymes, which help in providing a site in the host cell. With a wide application range of this technology, we see that the recombinant DNA technology industry has a high market value and many competitors. For example, the United States administered Recombinant Influenza Vaccine, which was introduced to protect against the seasonal influenza virus. As of the 2021-22 season, the USA had distributed over 174 million doses. The vaccine is produced using recombinant DNA technology. CDC has estimated that there were nearly 7.4 to 12 million flu illnesses in the 2021-22 season; hence, the vaccines made it possible to reduce the number of deaths caused by flu in the given year. Key Industry Drivers - Investments in R&D, Producing Transgenic Animals, Genetically Modified Crops, Vaccines rDNA technology has been used increasingly in the global scenario having various positive outcomes, and companies are investing heavily in the sector. The Malaghan Institute of Medical Research, based in Wellington, New Zealand, announced in May 2022 that it would invest USD 40 million over the next 4 years in developing vaccines as a part of its development program. As a whole, with technology advancing at a rapid pace, there will be further investment in the sector that will accelerate the industry's growth. Poultry, livestock, and pisciculture industries have benefited from using rDNA technology due to the improved yield of the products of the respective industries. The AquAdavantage salmon is an example of a transgenic fish developed by the company AquaBounty Technology by using the growth hormone from the Chinook variety of salmon to reduce the time period in which they grow. The dairy industry also makes use of the developments; for example, the recombinant bovine somatotropin (rBST) hormone greatly improved the health of dairy and beef cattle, improving the output of the industry, which in turn is expediting the recombinant DNA technology market analysis. In a study conducted by Fesseha et al. (2020) showed that, on average, the use of rBST increased the total output by 14.7% per day. Genetically modified crops have been grown since the mid-1990s.The first ever commercially genetically modified (GM) crop was the ‘Flavr Savr’ tomato developed by Calgene, an American genetic engineering company. Following this, companies developed other GM crops, namely - soybean, cotton, and corn, which are widely used. As of 2020, according to the US Department of Agriculture (USDA), over 90% of the land used for growing corn and soybean is through genetically modified seeds to be resistant to pests and weeds. With climate change and more resistant forms of pests and weeds, there would be a need to produce more advanced GM crops. Vaccines are used to prevent major diseases, and the first vaccine approved using recombinant DNA technology was the hepatitis B virus (HBV) vaccine. Another commonly used rDNA vaccine is the HPV vaccine. Using the recombinant DNA technology, there were several companies and institutes, such as Karolinska Institute in collaboration with Cobra Biologics, amongst others, that developed rDNA vaccines. According to the CDC, over 1 billion vaccine doses, including Covid, were given in the year 2021. Therefore, there is huge potential to develop vaccines using recombinant DNA technology, thereby augmenting its industry growth. Restraints The restraint for a company in the industry is the time consumed in developing new products, which also implies a high investment in the sector. At times, there are objections from the public towards using GM products. Opportunities - CRISPR, Therapeutic Applications, Gene Therapy Clustered regularly interspaced short palindromic repeats or widely known as CRISPR is a method by which prokaryotes defend themselves against viruses. The discovery of the CRISPR genome editing method was named “Breakthrough of the Year” by Science Magazine in 2015. In the year 2018, the U.S. FDA approved a clinical trial for using the CRISPR/Cas mode of gene editing as a therapy for people having a gene mutation causing blindness at birth. The widespread and undiscovered application of this technology presents itself as a tremendous opportunity for recombinant DNA technology. There are several trials underway for the use of recombinant DNA technology for human applications. The diseases in focus are cancer and AIDS. Eli Lilly, an American pharmaceutical company, produced Humulin - artificial insulin to aid in the condition of diabetes, using recombinant DNA technology. According to the CDC, over 37 million Americans have diabetes, and 20% of the cases are undiagnosed. According to the CDC, there are over 48 million human papillomaviruses (HPV) infections. The vaccine was developed in 1990 and helped reduce the number of active infections significantly. With the discovery of insulin and the HPV vaccine using recombinant DNA technology, there is huge scope for the discovery and application of more human enzymes and cures for diseases. Gene therapy is a method used to modify and /or manipulate gene expression to treat or cure a disease. An FDA-approved drug for type 1 spinal muscular atrophy, ZOLGENSMA, was developed by Novartis and approved for use in October 2021. The development of gene therapies aids in enhancing or reducing gene expressions to control and prevent diseases. Thus, we can see that further research in gene therapy would enhance a company’s opportunity in the market to treat complicated diseases. Recombinant DNA Technology Market Analysis Of Different Segments Covered in the Report Based on Product: Therapeutic Agent Vaccine Genetically Modified Crops Specialty Chemicals Based on Component: Expression System Cloning Vector Based on Application Food and Agriculture Environment Health Disease Fighting Based on End User Academic & Government Research Institutes Biotechnological and Pharmaceutical Companies Others Regional Coverage Analysis North America USA Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific Australia China India Japan South Korea The Middle East and Africa GCC South Africa Rest of the Middle East and Africa South America Argentina Brazil Rest of South America Segments Analysis & Insights Going by the product segmentation, The Therapeutic agent segment led the recombinant DNA technology market growth in all aspects in 2020. Therapeutic agents are those which are used for the treatment of an ailment or disease. Several therapeutic agents have been FDA approved and used for various diseases and conditions. For example, the FDA approved EPOGEN, which was erythropoietin alfa in 2007 and has been used to treat anemia caused by renal failure and HIV infection cancers. The recombinant DNA technology in plants has helped produce genetically modified crops. According to the USDA, in 2013, approximately half of the land to grow crops was used for growing genetically modified crops. Further, according to the USDA, on average, fruit and nut crops generate USD 25 billion in cash receipts in the farming industry. In 2017, Okanagan Speciality fruits developed a GM fruit, specifically a GM apple named ‘Arctic Apple’ with the feature of non-browning when exposed to oxygen. Therefore, further development of GM crops and therapeutic agents would increase the revenue sources for companies in the market. Going by application, the health and disease diagnostics segments would be at par with the food and agriculture segments due to the wide range of applications in each sector. Follicle-stimulating hormone (FSH) is an important hormone useful in sexual development and the sexual health cycle. FDA had approved artificial FSH, which is developed using recombinant DNA technology by Ferring Pharmaceuticals. It is sold under the brand name Bravelle. According to the CDC, among women aged from 15 to 49 with no prior birth history, 19% (1 out of 5) are unable to get pregnant after one year of trying. Therefore, medications like Bravelle are extremely helpful. Interferon is a naturally occurring group of proteins that help fight viruses. However, due to various medical conditions, the body may not be able to produce interferon. In such cases, it is necessary to inject artificially produced interferon. Interferon, developed by two companies, namely Hoffman-La Roche Inc. and Schering-Plough Corporation, was the first to get approval for interferon alfa by the FDA in 1986. Following this, other companies also began R&D and received approvals for other forms of interferon. Ampicillin is an example of a drug created using recombinant DNA technology. It treats various throat, neck, lung, GI infections, and other infections such as meningitis. In the food industry, lysozyme is a critical enzyme that is used to preserve foods. It prevents the growth of microorganisms that are prone to spoil food. According to the FDA, more than 95% of all animals reared for dairy and meat consume feed that is made from GM crops. The increase in dairy cattle's milk yield is due to bovine somatotropin use. FDA approved the use of the hormone, which is sold under the brand name Polisac. Going by region, North America holds the highest industry share at 52.3%. This is because of the high number of pharmaceutical and biotechnological companies and research institutes in the region. In 2021, Fujifilm Diosynth Biotechnologies invested USD 2 billion in facility expansion. As asserted by the US Bureau of Economic Analysis, the biotechnology sector accounted for nearly 1.5% of the US economy's total GDP. With policies and infrastructure in place that favor the setting up of businesses in the region, it makes for an attractive destination for investment in the market. Recombinant DNA Technology Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 707.20 billion The revenue forecast in 2030 USD 1378.76 billion Growth rate CAGR of 7.7 % The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Product, Component, Application, End User, and Region. By Product Therapeutic Agent, Vaccine, Genetically Modified Crops, Speciality Chemicals By Application Food and Agriculture, Environment, Health, and Disease Fighting By End-User Biotechnology and Pharmaceutical Industries, Academic and Research Institutes, Others By Region North America, Europe, Asia-Pacific, and LAMEA Country Scope USA, South Korea, India, Brazil, and South Africa Company Usability Profiles Monsanto, Thermo Fisher Scientific Inc., Sanofi, Biogen, Novartis AG, Novo Nordisk, GenScript, Pfizer, BASF, Bayer, DuPont Pioneer, Amgen Recombinant DNA Technology Market Competitive Landscape Analysis The market is highly attractive for investments and attracts many companies to it. The major players in the industry are: Monsanto Thermo Fisher Scientific Inc. Sanofi Biogen Novartis AG Novo Nordisk GenScript Pfizer BASF Bayer DuPont Pioneer Amgen Recent Developments In June 2022, Samsung Bioepis announced SB12, which is a proposed biosimilar to Soliris (eculizumab), which aids in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Soliris is a humanized monoclonal (IgG2/4), created in an NS0 cell line using recombinant DNA technology, which is used to treat PNH & hemolytic uremic syndrome in both adults & children (aHUS). In May 2022, the European Medicines Agency approved the use of Xenpozyme (olipudase alfa) for the treatment of Niemann - Pick disease, which is a rare genetic disorder affecting the body’s ability to metabolize fat. It was developed by Sanofi using recombinant DNA technology. On April 2022, the U.S. Food & Drug Administration (FDA) approved the commercial licensing of Novartis' multi-product, Recombinant DNA technology-driven gene therapy manufacturing facility in Durham. This authorization enabled the cutting-edge, 170,000-square-foot facility to manufacture, test, and commercially market Zolgensma and gene therapy products for ongoing and upcoming clinical trials. On Jan 2022, Thermo Fisher Scientific successfully bought the Recombinant DNA technology-based protein Maker Company Prepro Tech worth USD 1.85 Billion. The NJ (New Jersey) based Prepro Tech adequately provides cytokines & its related products that are used widely in fermentation-based production of drugs and in cell culture. Now, it has become a part of Thermo Scientific’s business, where it will contribute to cell culture offerings and bioprocessing. In December 2021, CORBEVAX was approved by the worldwide governments for emergency use as a vaccine against COVID-19. It was developed using recombinant DNA technology. Corbevax, a "recombinant protein sub-unit" vaccine, is made from a specific SARS-CoV-2 virus portion, the spike protein that may be seen on the virus's surface. The spike protein enables the virus to enter cells, where it may proliferate and transmit the disease. Since the body will already be prepared for an immune response when a real virus tries to invade, it is unlikely that the virus will cause significant harm to the body. In November 2021, American medicine and vaccine producer Zoetis, a subsidiary of Pfizer, developed and distributed COVID-19 vaccines meant for animals and livestock. The technology used was subunit recombinant DNA technology. The advantage of manufacturing COVID-19 vaccines with Recombinant DNA technology leads to their improved efficacy and greater response predictability compared to the other vaccines. Products that the Industry Leaders are Manufacturing Name Feature Key Player Humulin Controls Blood Sugar Levels. Lilly Pharma Humatrope Aids in people with SHOX deficiency aids growth for those with Turner’s Syndrome and aids growth in idiopathic short stature. Lilly Pharma GoldenRice Vitamin A enhanced rice. Monsanto / Bayer AquAdvantage The reduced growth period for salmon. AquaBounty Tech Frequently Asked Question About This Report Which are the prominent market players across the globe? The major players in the market are Monsanto, Thermo Fisher Scientific Inc., Sanofi, Biogen, Novartis AG, Novo Nordisk, GenScript, Pfizer, BASF, Bayer, DuPont Pioneer, Amgen What is Recombinant DNA Technology? Recombinant DNA Technology or RDT for short, is the use of enzymes, laboratory techniques and processes to bring about changes in the DNA of species and introducing it to a separate species to get a desired output of the resultant combination of genes. What was the global size in 2020? The market size for the recombinant DNA technology in 2020 was USD 656.34 billion. How big is the Recombinant DNA Technology Market ? The global Recombinant DNA Technology Market size was $707.20 billion in 2021 and is predicted to reach $1378.76 billion by 2030 with a CAGR of 7.7%. How is recombinant DNA used in industry? The various uses of recombinant DNA are production of hormones, insulin and proteins for humans and insect resistant, high yield crops and gene therapy for various diseases. What is the popular technology of recombinant DNA technology? The popular technology is in developing genetically modified plants, crops and animals What are the key industry trends of the market? The key trends for the market are enhanced use of gene therapy, applications in the energy sector through producing biofuels such as bioethanol and biohydrogen as well as rapid development of use of therapeutic treatments over new drug developments. What are the growth estimates for market till 2030? The CAGR for the time period was 7.7%. What are 3 uses of recombinant DNA technology? Three uses of recombinant DNA technology are: - In producing artificial proteins and hormones for medical conditions. - Producing genetically modified crops with higher yield and insect resistance. - Developing genetically modified animals for higher output and disease resistance. What is the Recombinant DNA Technology Market growth? The global Recombinant DNA Technology Market is expected to grow at a compound annual growth rate (CAGR) of 7.7% from 2021 to 2030 to reach USD $1378.76 billion by 2030. Sources https://www.ers.usda.gov/data-products/adoption-of-genetically-engineered-crops-in-the-u-s/recent-trends-in-ge-adoption/ https://www.cdc.gov/vaccines/covid-19/retail-pharmacy-program/index.html https://www.ers.usda.gov/publications/pub-details/?pubid=45182 https://www.fda.gov/consumers/consumer-updates/fda-ensures-your-foods-animals-are-safe 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Recombinant DNA Technology Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Recombinant DNA Technology Market 4.2.1 market, 2021 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 market, By Product, 2021 - 2030 (USD Million) 4.5 By Application Business Analysis 4.5.1 market, By Application, 2021 - 2030 (USD Million) 4.6 Component Business Analysis 4.6.1 market, By Component, 2021 - 2030 (USD Million) 4.7 End-User Business Analysis 4.7.1 market, By End-User, 2021 - 2030 (USD Million) 4.8 Value Chain Analysis 4.9 Market Variable Analysis 4.9.1 Market Drivers Analysis 4.9.2 Market Restraints Analysis 4.10 Business Environment Analysis Tool 4.10.1 market PEST analysis 4.10.2 market Porter’s analysis 4.11 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-User Analysis 5.11.1. Trends in End-User (2014-2021) 5.11.2. Trends in End-User (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By Region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Manufacturing Sites, Area Served, Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Therapeutic Agent 7.3.1. Therapeutic Agent market, 2021 - 2030 (USD Million) 7.4. Vaccine 7.4.1. Vaccine market, 2021 - 2030 (USD Million) 7.5. Genetically Modified Crops 7.5.1. Genetically Modified Crops market, 2021 - 2030 (USD Million) 7.6. Speciality Chemicals 7.6.1. Speciality Chemicals market, 2021 - 2030 (USD Million) 8. Market: By Application Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Food and Agriculture 8.3.1. Food and Agriculture Market, 2021 - 2030 (USD Million) 8.4. Environment 8.4.1. Environment market, 2021 - 2030 (USD Million) 8.5. Health 8.5.1. Health market, 2021 - 2030 (USD Million) 8.6. Disease Fighting 8.6.1. Disease Fighting market, 2021 - 2030 (USD Million) 9. Market: By Component Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Expression System 9.3.1. Expression System market, 2021 - 2030 (USD Million) 9.4. Cloning Vector 9.4.1. Cloning Vector market, 2021 - 2030 (USD Million) 10. Market: By End-User Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Academic & Government Research Institutes 10.3.1. Academic & Government Research Institutes market, 2021 - 2030 (USD Million) 10.4. Biotechnological and Pharmaceutical Companies 10.4.1. Biotechnological and Pharmaceutical Companies market, 2021 - 2030 (USD Million) 10.5. Others 10.5.1. Others Market, 2021 - 2030 (USD Million) 11. Market: Regional Outlook 11.1 North America 11.1.1. North America market, By Product, 2021 - 2030 (USD Million) 11.1.2. North America market, By Application, 2021 - 2030 (USD Million) 11.1.3. North America market, by End-User, 2021 - 2030 (USD Million) 11.1.4. North America market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. market, By Product, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. market, By Application, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. market, by End-User, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada market, By Product, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada market, By Application, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada market, by End-User, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe market, By Product, 2021 - 2030 (USD Million) 11.2.2. Europe market, By Application, 2021 - 2030 (USD Million) 11.2.3. Europe market, by End-User, 2021 - 2030 (USD Million) 11.2.4. Europe market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. market, By Product, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. market, By Application, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. market, by End-User, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany market, By Product, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany market, By Application, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany market, by End-User, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France market, By Product, 2021 - 2030 (USD Million) 11.2.4.3.2. France market, By Application, 2021 - 2030 (USD Million) 11.2.4.3.3. France market, by End-User, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe market, By Product, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe market, By Application, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe market, by End-User, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific market, By Product, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific market, By Application, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific market, by End-User, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China market, By Product, 2021 - 2030 (USD Million) 11.3.4.1.2. China market, By Application, 2021 - 2030 (USD Million) 11.3.4.1.3. China market, by End-User, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India market, By Product, 2021 - 2030 (USD Million) 11.3.4.2.2. India market, By Application, 2021 - 2030 (USD Million) 11.3.4.2.3. India market, by End-User, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan market, By Product, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan market, By Application, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan market, by End-User, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea market, By Product, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea market, By Application, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea market, by End-User, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC market, By Product, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC market, By Application, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC market, by End-User, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America market, By Product, 2021 - 2030 (USD Million) 11.4.2. Latin America market, By Application, 2021 - 2030 (USD Million) 11.4.3. Latin America market, by End-User, 2021 - 2030 (USD Million) 11.4.4. Latin America market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil market, By Product, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil market, By Application, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil market, by End-User, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico market, By Product, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico market, By Application, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico market, by End-User, 2021 - 2030 (USD Million) 11.4.4.3. Rest of Latin America 11.4.4.3.1. Rest of the Latin America market, By Product, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America market, By Application, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America market, by End-User, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA market, By Product, 2021 - 2030 (USD Million) 11.5.2. MEA market, By Application, 2021 - 2030 (USD Million) 11.5.3. MEA market, by End-User, 2021 - 2030 (USD Million) 11.5.4. MEA market, by region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 MONSANTO 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Product Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Thermo Fisher Scientific Inc 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Product Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Sanofi 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Product Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Biogen 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Product Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. Novartis AG 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Product Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Novo Nordisk 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Product Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. GENSCRIPT 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Product Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. PFIZER 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Product Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. BASF 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Product Portfolio Analysis 12.9.4. Business Strategy & Recent Development 12.10. Bayer 12.10.1. Company overview 12.10.2. Financial performance 12.10.3. Product Portfolio Analysis 12.10.4. Business Strategy & Recent Development 12.11. DuPont Pioneer 12.11.1. Company overview 12.11.2. Financial performance 12.11.3. Product Portfolio Analysis 12.11.4. Business Strategy & Recent Development 12.12. Amgen 12.12.1. Company overview 12.12.2. Financial performance 12.12.3. Product Portfolio Analysis 12.12.4. Business Strategy & Recent Development List of Tables (58 Tables) TABLE 1. MARKET, By Product, 2021-2030 (USD Million) TABLE 2. MARKET FOR Therapeutic Agent, BY REGION, 2021-2030 (USD Million) TABLE 3. MARKET FOR Vaccine, BY REGION, 2021-2030 (USD Million) TABLE 4. MARKET FOR Genetically Modified Crops, BY REGION, 2021-2030 (USD Million) TABLE 5. MARKET FOR Speciality Chemicals, BY REGION, 2021-2030 (USD Million) TABLE 6. MARKET, By Application, 2021-2030 (USD Million) TABLE 7. MARKET FOR Food and Agriculture, BY REGION, 2021-2030 (USD Million) TABLE 8. MARKET FOR Environment, BY REGION, 2021-2030 (USD Million) TABLE 9. MARKET FOR Health, BY REGION, 2021-2030 (USD Million) TABLE 10. MARKET FOR Disease Fighting, BY REGION, 2021-2030 (USD Million) TABLE 11. MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 12. MARKET FOR Academic & Government Research Institutes, BY REGION, 2021-2030 (USD Million) TABLE 13. MARKET FOR Biotechnological and Pharmaceutical Companies, BY REGION, 2021-2030 (USD Million) TABLE 14. MARKET FOR Others, BY REGION, 2021-2030 (USD Million) TABLE 15. MARKET, By Component, 2021-2030 (USD Million) TABLE 16. MARKET FOR Expression System, BY REGION, 2021-2030 (USD Million) TABLE 17. MARKET FOR Cloning Vector, BY REGION, 2021-2030 (USD Million) TABLE 18. MARKET, BY REGION, 2021-2030 (USD Million) TABLE 19. NORTH AMERICA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 20. NORTH AMERICA MARKET, By Product, 2021-2030 (USD Million) TABLE 21. NORTH AMERICA MARKET, By Application, 2021-2030 (USD Million) TABLE 22. NORTH AMERICA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 23. EUROPE MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 24. EUROPE MARKET, By Product, 2021-2030 (USD Million) TABLE 25. EUROPE MARKET, By Application, 2021-2030 (USD Million) TABLE 26. EUROPE MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 27. ASIA-PACIFIC MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 28. ASIA-PACIFIC MARKET, By Product, 2021-2030 (USD Million) TABLE 29. ASIA-PACIFIC MARKET, By Application, 2021-2030 (USD Million) TABLE 30. ASIA-PACIFIC MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 31. LAMEA MARKET, BY COUNTRY, 2021-2030 (USD Million) TABLE 32. LAMEA MARKET, By Product, 2021-2030 (USD Million) TABLE 33. LAMEA MARKET, By Component, 2021-2030 (USD Million) TABLE 34. LAMEA MARKET, BY END-USER, 2021-2030 (USD Million) TABLE 35. MONSANTO: COMPANY SNAPSHOT TABLE 36. MONSANTO: OPERATING SEGMENTS TABLE 37. Thermo Fisher Scientific Inc: COMPANY SNAPSHOT TABLE 38. Thermo Fisher Scientific Inc: OPERATING SEGMENTS TABLE 39. Sanofi: COMPANY SNAPSHOT TABLE 40. Sanofi: OPERATING SEGMENTS TABLE 41. Biogen: COMPANY SNAPSHOT TABLE 42. Biogen: OPERATING SEGMENTS TABLE 43. Novartis AG: COMPANY SNAPSHOT TABLE 44. Novartis AG: OPERATING SEGMENTS TABLE 45. Novo Nordisk: COMPANY SNAPSHOT TABLE 46. Novo Nordisk: OPERATING SEGMENTS TABLE 47. GENSCRIPT: COMPANY SNAPSHOT TABLE 48. GENSCRIPT: OPERATING SEGMENTS TABLE 49. PFIZER: COMPANY SNAPSHOT TABLE 50. PFIZER: OPERATING SEGMENTS TABLE 51. BASF: COMPANY SNAPSHOT TABLE 52. BASF: OPERATING SEGMENTS TABLE 53. Bayer: COMPANY SNAPSHOT TABLE 54. Bayer: OPERATING SEGMENTS TABLE 55. DuPont Pioneer: COMPANY SNAPSHOT TABLE 56. DuPont Pioneer: OPERATING SEGMENTS TABLE 57. Amgen: COMPANY SNAPSHOT TABLE 58. Amgen: OPERATING SEGMENTS List of Figures (24 Figures) Figure 1 Market: Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries: Market Figure 4 Research Methodology: Hypothesis Building Figure 5 Market: Product-Based Estimation Figure 6 Top 12 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2021 Figure 8 Import Data for Recombinant DNA Technology, By Country, 2016–2021 (USD Thousand) Figure 9 Export Data for Recombinant DNA Technology, By Country, 2016–2021 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 Market, By Application, 2019 vs. 2025 (USD Million) Figure 12 Market Share, By End-User, 2019 vs. 2025 (USD Million) Figure 13 Market Share, By Product, 2019 vs. 2025 (USD Million) Figure 14 Market Share, By Component, 2019 vs. 2025 (USD Million) Figure 15 Geographical Snapshot of the Market Figure 16 Therapeutic Agent to Witness Higher CAGR in the Market for Product Segment during the Forecast Period. Figure 17 Health & disease to Witness Higher CAGR in Market for Application Segment during Forecast Period. Figure 18 North America Accounted for the Largest Share of the Market, By Regional Basis, in 2019 Figure 19 Market: Drivers, Restraints, Opportunities, and Challenges Figure 20 North America: Market Snapshot Figure 21 Asia Pacific: Market Snapshot Figure 22 Vendor Dive: Evaluation Overview